Is NCT07027514 recruiting in Detroit, MI?

Yes, NCT07027514 is currently recruiting participants at its Detroit, MI location. This non small cell lung cancer clinical trial is actively enrolling qualified participants.

How do I join the non small cell lung cancer clinical trial in Detroit?

To join this clinical trial in Detroit, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Detroit clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non Small Cell Lung Cancer Clinical Trial in Detroit, MI

About This Non Small Cell Lung Cancer Study in Detroit

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

Sponsor: Ankyra Therapeutics, Inc

Who Can Participate

Inclusion Criteria

Have confirmed locally advanced or metastatic NSCLC

Thyroid-stimulating hormone (TSH) within normal limits

Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1

Have a life expectancy \> 12 weeks

Have baseline electrocardiogram (ECG) without evidence of acute ischemia or prolonged QT interval

Heterosexually active women of childbearing potential (WOCBP) must agree to use at least 2 forms of highly effective methods of contraception

All male participants who are not sterile must commit to the use of a reliable method of birth control or abstinence

Human immunodeficiency virus (HIV)-infected participants must be on anti-retroviral therapy (ART) and have well-controlled HIV infection/disease

Resolution of all prior anticancer therapy toxicities to ≤ Grade 1 prior to C1D1.

Willingness to provide fresh tumor biopsy specimens

Capable of understanding and complying with protocol requirements

Provides written informed consent for the study

Exclusion Criteria

Cohort A only: Participants with Grade 3 or higher toxic effects to manage adverse events from previous treatment with immunotherapy

Cohort B only: Prior therapy with an immune checkpoint inhibitor.

Have known EGFR or ALK mutations

Have had prior treatment with recombinant interleukin-12 (IL-12)

Have received short-term systemic therapy with immunosuppressive agents prior to C1D1

Have active autoimmune disease or medical conditions requiring chronic steroid or other immunosuppressive therapy prior toC1D1

Have received live vaccines within 28 days prior to C1D1

Have primary or acquired immunodeficient states

Women of childbearing potential who has a positive serum pregnancy test prior to C1D1 or female participant who is breastfeeding

Have a history of allogeneic tissue/solid organ transplant

Has known active uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV).

HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease

Have known active central nervous system metastases

Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias.

Have uncontrolled bleeding disorders prior to C1D1

Participants on coumadin (warfarin), due to potential for increased bleeding risk associated with surgery

History of noninfectious pneumonitis within the previous 5 years

Cohort A only: History of allergy to protein-based therapies, history of any significant drug allergy, or known allergies, hypersensitivity, or intolerance to cetrelimab excipients OR Cohort B only: Hypersensitivity to any component of the anti-PD-1/PD-L1 antibody selected as standard of care

Have other systemic conditions or organ abnormalities that may interfere with the conduct of the study

Have any acute or chronic psychiatric problems or substance abuse disorder that make the participant unsuitable for participation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT07027514) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non Small Cell Lung Cancer Treatment Options in Detroit, MI

If you're searching for non small cell lung cancer treatment options in Detroit, MI, this clinical trial (NCT07027514) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

Non Small Cell Lung Cancer Clinical Trial in Detroit, MI

Expert Care in Detroit

IRB Approved

No-Cost Care

Apply for This Detroit Location

Why Participate?

Simple Process